The primary objective of this study is to evaluate the safety and efficacy of Larazotide
(AT1001) versus placebo in children and young adults 7 to ≤21 years of age who present with
symptoms of Long COVID in the presence of SARS-CoV-2 antigenemia. AT1001 (n=32) or placebo
(n=16) will be administered orally four times a day (QID) for 21 days.